Curaleaf products display at Curaleaf store in Queens in New York, U.S., on Thursday, Oct.18, 2018. (Photo: Jeenah Moon/Bloomberg)
Federal regulators last Tuesday threatened cannabis giant Curaleaf with possible legal action for allegedly making unsubstantiated medical claims about the cannabidiol, or CBD, products on its website and on social media.
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- All PropertyCasualty360.com news coverage, best practices, and in-depth analysis.
- Educational webcasts, resources from industry leaders, and informative newsletters.
- Other award-winning websites including BenefitsPRO.com and ThinkAdvisor.com.
Already have an account? Sign In
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
